NuGenerex Gets CE Mark for Point-of-Care Syphilis Assay

Jan 24, 2019

|

NEW YORK (360Dx) — NuGenerex Diagnostics announced today that it has received CE marking for its rapid, point-of-care syphilis test called the Express II Syphilis TreponemalAssay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

NuGenerex Gets CE Mark for Point-of-Care Syphilis Assay

To read the full story....

Breaking News

CDC Study Finds Abbott BinaxNow SARS-CoV-2 Antigen Test Less Sensitive Than PCR, But Still Useful

Devyser Receives €750K Grant to Build Sequencing Assay for Early Detection of Transplant Rejection

Hamilton Storage, Harvard Spinout Rhinostics Partner for High-Throughput Sample Processing

Ortho Clinical Diagnostics Launches IPO at $20 to $23 Per Share

Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Lucira Health Files for $115M IPO

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Ortho Clinical Diagnostics Launches IPO at $20 to $23 Per Share

At JP Morgan Conference, Quidel CEO Discusses Plan to Enter OTC Infectious Disease Test Market

Lucira Health Files for $115M IPO

Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

Finnish Diagnostic Firm Actim Gets CE Mark for SARS-CoV-2 Antibody Test

Sponsorships